HIF-1α falls short, ERCC-1 stands out: Predictive insights in locally advanced cervical cancer.
Makaleler > Tam Makale · 2026
Yazarlar: Fatma Sert, Gurdeniz Serin, Senem Alanyali, Meltem Ozturk, Mert Delikaya, Osman ZEKİOĞLU, Zeynep ÖZSARAN
Histology and histopathology, Uluslararası, 2026, ss 25125-25125
DOI: 10.14670/hh-25-125
Özet
BACKGROUND: This study aimed to evaluate the association between pretreatment immunohistochemical expression of hypoxia-inducible factor 1 alpha (HIF-1α) and excision repair cross-complementation group 1 (ERCC1) and clinical outcomes in patients with locally advanced cervical cancer (LACC) treated with definitive concurrent radiochemotherapy (cRCT). METHODS: Eighty-seven patients with histologically confirmed LACC who received definitive cRCT between 2005 and 2015 were retrospectively analyzed. Immunohistochemical staining for HIF-1α and ERCC1 was performed on pretreatment biopsy specimens, and H-scores were calculated semi-quantitatively. Receiver operating characteristic (ROC) curve analysis determined optimal cut-off values: ≤100 and >100 for HIF-1α, and ≤130 and >130 for ERCC1. Overall survival (OS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were estimated using the Kaplan-Meier method, and prognostic variables were analyzed with Cox regression models. RESULTS: =0.038). HIF-1α expression showed no significant association with any survival outcome. CONCLUSIONS: High ERCC1 expression was an independent prognostic indicator for poor LRFS, suggesting its potential as a biomarker of radioresistance. In patients with elevated ERCC1, alternative non-platinum agents may be considered. HIF-1α had no predictive or prognostic value in this cohort.